The healthcare businesses most likely to draw scrutiny in 2026, per DJ Holt Law [operator-intel]
DJ Holt Law published a July 1, 2026 piece arguing that enforcement agencies are using data analytics to flag operational anomalies, and that multi-location med spas, IV hydration clinics, and integrated digital-health platforms sit near the top of the exposure list (djholtlaw.com). This is a law firm's read on enforcement targeting, not a specific action, but the profile it draws is the profile most peptide and HRT operators fit: multi-site, cash-pay, telehealth-enabled, growing faster than the compliance built for a single clinic. The useful takeaway is not fear, it is triage: know whether your own footprint matches the pattern regulators reportedly screen for. Have counsel map your structure against the risk factors the piece names and fix the one or two that are cheapest to close before an audit finds them for you.
Source: djholtlaw.com (2026-07-01)

FTC files an amicus brief against a pharmaceutical monopoly claim [marketing-compliance]
The FTC filed an amicus brief on June 23, 2026 in an antitrust case alleging that a drug manufacturer illegally maintained a monopoly through anticompetitive conduct (ftc.gov). The case is upstream of any clinic, but the signal is the agency's continued appetite for pharmaceutical-market conduct cases, and that appetite shapes the competitive terrain you buy and sell in. Supply consolidation, exclusive arrangements, and pricing behavior among the manufacturers and distributors behind your formulary are exactly what this attention targets. There is no action item on your desk today, but track how these cases move, because they set the rules for the supply market your margins depend on. File it under market intelligence and revisit if a supplier you rely on turns up in a similar matter.
Source: ftc.gov (2026-06-23)

FTC and states sue over unsubstantiated pediatric treatment claims [marketing-compliance]
The FTC, joined by Alaska, Iowa, Nebraska, and Texas, sued the World Professional Association for Transgender Health on June 17, 2026, alleging it provided the means for providers to make false and unsubstantiated claims to parents (ftc.gov). Set the underlying subject aside and read the enforcement theory: the FTC is treating unsubstantiated health-outcome claims as deceptive and is willing to reach the organizations that supply the claims, not just the providers who repeat them. Any hormone-therapy marketer running outcome claims in ad copy, provider scripts, or intake materials should read the substantiation standard the complaint asserts. Have counsel audit your marketing claims for the evidence behind them, and treat borrowed claims from a supplier or association as your own exposure once they hit your funnel.
Source: ftc.gov (2026-06-17)

A warning-letter lesson for device makers, from FDA's Happiest Baby action [operator-intel]
Hyman, Phelps & McNamara used FDA's warning letter to Happiest Baby to draw compliance lessons for device manufacturers (June 23, 2026, thefdalawblog.com). This is analysis, secondary to the warning letter itself, and the product is a sleep sack rather than anything in your formulary, but the transferable point is how a marketing claim turned a consumer product into a regulated device in FDA's eyes. Clinics that sell adjacent wellness devices, diagnostics, or at-home kits alongside their core service inherit the same risk: the claim, not the object, is what pulls a product into device regulation. Read the letter for the claim language that triggered it, then check whether anything you market crosses the same line.
Source: thefdalawblog.com (2026-06-23)

PCI Pharma applies to import controlled substances [compounding-bulks]
DEA published a notice on June 17, 2026 that AndersonBrecon, Inc., doing business as PCI Pharma Services, has applied for registration as an importer of controlled substances (federalregister.gov). It is an application, not a grant, and it changes nothing on publication. PCI is a large contract packaging and clinical-supply operation, so its import posture is one more data point on where scheduled-substance capacity is consolidating among the contract manufacturers your pharmacy partners may sit downstream of. Supply-chain signal, not a regulatory change to which substances a clinic may compound. If your compounding relationships touch the classes named in the notice, pull it and confirm your partners have a qualified second source.
Source: federalregister.gov (2026-06-17)

Confirm no supplier carries mitragynine pseudoindoxyl, MGM-15, or MGM-16, and watch the Federal Register for the temporary order.

Audit your marketing claims against the substantiation standard the FTC is asserting in the claims cases above.

Map your footprint against the enforcement risk factors and close the one or two cheapest gaps.

Seventeen days to the July 23-24 PCAC advisory meeting: lock your compounding pharmacy's written position on the seven peptides.

Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (2026-07-06, federalregister.gov)

FTC Files Amicus Brief to Protect Consumers from Pharmaceutical Monopolies (2026-06-23, ftc.gov)

FTC, States Sue World Professional Association for Transgender Health Over Deceptive Claims (2026-06-17, ftc.gov)

Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services (2026-06-17, federalregister.gov)

PCAC advisory meeting July 23-24, 2026 on seven peptides for the 503A bulks list (Federal Register 2026-07361, published 2026-04-16; docket FDA-2025-N-6895). Advisory recommendation only; FDA decides through rulemaking.

The Healthcare Businesses Most Likely to Trigger Scrutiny in 2026 (djholtlaw.com)

Small Sleep Sacks, Big Compliance Lessons: FDA's Happiest Baby Warning Letter (thefdalawblog.com)

None today.